Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 5Rectal Neoplasms 2Melanoma 2Colonic Neoplasms 2Neurofibromatosis 1 1Lymphatic Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 59Carboplatin 56Pemetrexed 47Cisplatin 39Paclitaxel 24Nivolumab 23Docetaxel 21durvalumab 20Gemcitabine 15130-nm albumin-bound paclitaxel 14osimertinib 13Cetuximab 12Specimen Handling 11Magnetic Resonance Spectroscopy 11atezolizumab 10amivantamab 8Taxes 8Radiotherapy 8Radiosurgery 7Ipilimumab 7lazertinib 6alectinib 6Ramucirumab 6Observation 6Bevacizumab 6cemiplimab 5Leucovorin 5Fluorouracil 5Etoposide 5Erlotinib Hydrochloride 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × encorafenib × 30 days × Clear all
NCT04800822 2026-06-04

PF-07284892 in Participants With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
53 enrolled
CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡